Themis obtains an exclusive licence from Merck to develop vaccine candidates with an undisclosed indication, using its measles virus vector-based platform.
Researchers show miniature livers can develop steatohepatitis and fibrosis, pointing to potential for personalized hepatic drug discovery and toxicity platforms.
Schrödinger secures further funding, extends collaboration with Morphic Therapeutic on computational discovery platform for oral integrin drugs for the second time.
Veeva Systems launches a software application aiming to reduce the time and effort of manual data entry, which will be integrated to its cloud-based suite.
Engineered cardiac tissues generated using Tara Biosystems' heart-on-a-chip system predict how patients will respond to a range of drugs, as demonstrated in a recent study with GSK.
The multi-stakeholder group is developing a blockchain-powered platform to increase transparency and collaboration in the clinical trial supply chain – and has successfully completed a proof-of-concept project, now looking to next steps.
Onconova to use Mission Bio’s Tapestri targeted single-cell DNA analysis platform to advance its cancer therapy, rigosertib, into Phase III clinical trials.
Cancer Research UK to support the clinical development of Hummingbird’s investigative cancer treatment which has the potential to fight drug resistant tumours.
Acclinate Genetics launches e-DICT, a clinical trials management system aiming to close the gap between the population rate of minorities in the US and their participation rate in clinical trials.
Prellis advances its goal of using 3D holographic printing to create organoids for research and development – recently closing a $10.5m investment round to further develop its technology, which accelerates drug screening, says CEO.
HCL Technologies and Oracle Health Sciences announce a collaboration to “bridge the gap” between the potential of mobile health and the realities of adoption, says EVP.
At a time when innovation is rapid, clinical development is evolving at the same pace, and new technologies are bringing disruptive opportunities to research, says AbbVie executive.
